Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus Capecitabine vs Sintilimab in High-Risk NPC
NCT06900218Phase 3Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- May 2025
- Primary completion
- May 2030
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of capecitabine in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Planned start May 2025; status: not yet recruiting.
02
Drugs
capecitabine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06900218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06900218.